Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice

Psychopharmacology

Volumn 206, Issue 1, 2009, Pages 97-107

  Bourin, Michel ^a   Chenu, Franck ^a   Prica, Corina ^a   Hascoët, Martine ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

5 HT receptors; Antidepressants; Aripiprazole; Depression; Dopamine; Forced swimming test

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; DESIPRAMINE; MINALCIPRAN; PAROXETINE; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FORCED SWIMMING TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; MALE; MICE; PIPERAZINES; QUINOLONES; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL;

EID: 69049097023     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1583-7     Document Type: Article

References (49)

1. Y Ago S Nakamura A Baba T Matsuda 2005 Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex Neuropsychopharmacology 30 43 51
2. M Argyelan Z Szabo B Kanyo A Tanacs Z Kovacs Z Janka L Pavics 2005 Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study J Affect Disord 89 115 23
3. NM Barnes T Sharp 1999 A review of central 5-HT receptors and their function Neuropharmacology 38 1083 10152
4. M Berk S Dodd M Kauer-Sant'anna GS Malhi M Bourin F Kapczinski T Norman 2007 Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder Acta Psychiatr. Scand. Suppl. 434 41 49
5. RM Berman RN Marcus R Swanink RD McQuade WH Carson PK Corey-Lisle A Kan 2007 The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study J Clin Psychiatry 68 843 53
6. M Bourin MC Colombel JP Redrobe J Nizard M Hascoët GB Baker 1998 Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages Prog Neuropsychopharmacol Biol Psychiatry 22 343 351
7. KD Burris TF Molski C Xu E Ryan K Tottori T Kikuchi FD Yocca PB Molinoff 2002 Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 381 389
8. Chenu F, Dally E, Bourin M (2007) Effect of antidepressant drugs on 6-OHDA in the FST. Eur Neuropsychopharmacol 17:187-93
9. L Colonna M Petit JP Lepine 1979 Bromocriptine in affective disorders. A pilot study J Affect Disord 1 173 177
10. E Dailly F Chenu CE Renard M Bourin 2004 Dopamine, depression and antidepressants Fundam Clin Pharmacol 18 601 607
11. R Davis R Whittington HM Bryson 1997 Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression Drugs 53 608 36
12. A Dhir SK Kulkarni 2008 Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors Neurosci Lett 445 83 88
13. M El Mansari R Ghanbari S Janssen P Blier 2008 Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain Neuropharmacology 55 1191 8
14. M Huang J Ichiwaka Z Li J Dai HY Meltzer 2006 Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex Psychopharmacology (Berl) 185 274 81
15. J Ichikawa H Ishii S Bonaccorso WL Fowler IA O'Laughlin HY Meltzer 2001 5-HT(2A) and D(2) receptor blockade increases cortical dopamine release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J Neurochem 76 1521 1531
16. SR Joca LL Skalisz V Beijamini MA Vital R Andreatini 2000 The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission Eur. Neuropsychopharmacol 10 223 328
17. J Kamei S Miyata T Sunohara A Kamei M Shimada M Ohsawa 2008 Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test J Pharmacol Sci 108 381 384
18. M Landén ME Thase 2006 A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors Psychopharmacol Bull 39 147 66
19. SX Li KW Perry DT Wong 2002 Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats Neuropharmacology 42 181 90
20. Z Li J Ichikawa J Dai HY Meltzer 2004 Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain Eur J Pharmacol 493 75 83
21. J Maj Z Rogoz 1999 Synergistic effect of pramipexole and sertraline in the forced swimming test Pol J Pharmacol 51 471 475
22. RN Marcus RD McQuade WH Carson D Hennichen M Fava JS Simon MH Trivedi T Me RM Berman 2008 The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study J Clin Psychopharmacol 28 156 165
23. S Matsuyama K Nei C Tanaka 1997 Regulation of GABA release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus Brain Res 761 105 112
24. JH Meyer VS Goulding AA Wilson D Hussey BK Christensen S Houle 2002 Bupropion occupancy of the dopamine transporter is low during clinical treatment Psychopharmacology (Berl) 163 102 5
25. A Nakasato Y Nakatani Y Seki N Tsujino M Umino H Arita 2008 Swim stress exaggerates the hyperactive mesocortical dopamine system in a rodent model of autism Brain Res 1193 128 35
26. GG Nomikos G Damsma D Wenkstern HC Fibiger 1992 Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum Neuropsychopharmacology 7 7 14
27. GI Papakostas TJ Petersen AA Nierenberg JL Murakami JE Alpert JF Rosenbaum M Fava 2004 Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder J Clin Psychiatry 65 217 221
28. GI Papakostas TJ Petersen G Kinrys AM Burns JJ Worthington JE Alpert M Fava AA Nierenberg 2005 Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder J Clin Psychiatry 66 1326 1330
29. B Petit-Demoulière F Chenu M Bourin 2005 Forced swimming test in mice: a review of antidepressant activity Psychopharmacology 177 245 255
30. NS Philip LL Carpenter AR Tyrka LH Price 2008 Augmentation of antidepressants with atypical antipsychotics: a review of the current literature J Psychiatr Pract 14 34 44
31. MF Piacentini R Clinckers R Meeusen S Sarre G Ebinger Y Michotte 2003 Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat J Appl Physiol 95 652 6
32. RD Porsolt A Bertin M Jalfre 1977 Behavioural despair in mice: a primary screening test for antidepressants Arch Int Pharmacodyn 229 327 336
33. C Prica M Hascoët M Bourin 2008 Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? Behav Brain Res 194 92 99
34. MH Rapaport GM Gharabawi CM Canuso RA Mahmoud MB Keller CA Bossie I Turkoz RA Lasser A Loescher P Bouhours F Dunbar CB Nemeroff 2006 Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation Neuropsychopharmacology 31 2505 2513
35. CE Renard AJ Fiocco F Clenet M Hascoët M Bourin 2001 Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology 159 42 50
36. CE Renard E Dailly DJ David M Hascoët M Bourin 2003 Neurochemical changes following the mouse forced swimming test but not the tail suspension test Fundam Clin Pharmacol 17 449 455
37. CE Renard E Dailly BA Nic Dhonnchadha M Hascoët M Bourin 2004 Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test? Prog Neuropsychopharmacol Biol Psychiatry 28 1255 1259
38. H Rollema Y Lu AW Schmidt S Sprouse SH Zorn 2000 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the prefrontal cortex Biol Psychiatry 48 229 237
39. ZL Rossetti M Lai Y Hmaidan GL Gessa 1993 Depletion of mesolimbic dopamine during behavioral despair: partial reversal by chronic imipramine Eur J Pharmacol 242 313 315
40. JS Simon CB Nemeroff 2005 Aripiprazole augmentation of antidepressants for the treatment of partially responding and non responding patients with major depressive disorder J Clin Psychiatry 66 1216 1220
41. DA Shapiro S Renock E Arrington LA Chiodo LX Liu DR Sibley BL Roth R Mailman 2003 Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 1400 1411
42. B Shopsin S Gershon 1978 Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495) Neuropsychobiology 4 1 14
43. KN Sokolski 2008 Adjunctive aripiprazole for bupropion-resistant major depression Ann Pharmacother 42 1124 1129
44. SM Stahl 2001 Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 1. "Goldilocks" actions at dopamine receptors J Clin Psychiatry 62 841 842
45. SM Stahl 2001 Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 2. Illustrating their mechanism of action J Clin Psychiatry 62 923 924
46. SM Stahl JF Pradko BR Haight JG Modell CB Rockett S Learned-Coughlin 2004 A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor Prim Care Companion J Clin Psychiat 6 159 166
47. ST Szabo P Blier 2002 Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons J Pharmacol Exp Ther 302 983 91
48. ME Thase A Jonas A Khan CL Bowden X Wu RD McQuade WH Carson RN Marcus R Owen 2008 Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies J Clin Psychopharmacol 28 13 20
49. A Zocchi D Fabbri CA Heidbreder 2005 Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex Neurosci Lett 387 157 161